Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1628 publications
Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ?
Journal: Expert review of clinical pharmacology
Published: October 16, 2025
Remission of lichen amyloidosis achieved with upadacitinib: A case report.
Journal: JAAD case reports
Published: October 13, 2025
Treatment of systemic vasculitis.
Journal: Current opinion in rheumatology
Published: October 10, 2025
Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.
Journal: Italian journal of dermatology and venereology
Published: October 03, 2025
Treatment of Porokeratosis Ptychotropica With Upadacitinib.
Journal: JAMA dermatology
Published: October 01, 2025
Bullous pityriasis lichenoides et varioliformis acuta successfully treated with upadacitinib.
Journal: JAAD case reports
Published: September 25, 2025
Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
Journal: Se pu = Chinese journal of chromatography
Published: September 24, 2025
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.
Journal: Skin therapy letter
Published: September 24, 2025
Progress in the application of JAK inhibitors in atopic dermatitis
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: September 16, 2025
Upadacitinib in a Refractory Case of Alpha-1 Antitrypsin Deficiency-Related Panniculitis.
Journal: Cureus
Published: September 16, 2025
Treatment of refractory Hailey-Hailey disease with oral upadacitinib and topical ruxolitinib 1.5% cream.
Journal: JAAD case reports
Published: September 15, 2025
Last Updated: 10/31/2025